Low expression of Klotho, or high expression of CCL2 proteins in tumor tissues, could be correlated with poor overall survival of CRC patients, suggesting that CCL2 represents a promising relevant biomarker and potential target for CRC. The gene discussed is CCL2; the disease is neoplasm.